We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
由歐盟孤兒藥案件 談競爭法I與藥品超額定價問題.
- Authors
魏杏芳
- Abstract
The unique characteristics of orphan drug market and the right of exclusivity provide the incentives for pharmaceuticals to adopt excessive pricing. In recent years, three EU member states' competition authorities had fined the same orphan drug company, Leadiant, due to illegal excessive prices. European Commission also sanctioned Aspen because the medicine manufacture had imposed unfair prices, abused its dominant position and violated the EU competition law. All these facts reflect the trend that EU competition law has been used as a tool to tackle the exorbitantly high drug prices. The "UB test", i.e., cumulatively quantitative and qualitative analyses, is applied in those cases. The rules for prohibiting abuse of dominance in both EU and Taiwan have the common purposes and principles, therefore the practices and enforcement experiences in EU are valuable for use to learn.
- Publication
Angle Health Law Review, 2023, Issue 80, p116
- ISSN
2415-5306
- Publication type
Academic Journal
- DOI
10.53106/241553062023060080009